Gastro-protective effect of some statins against induced gastric ulcer in rats
Keywords:
Pharmaceutical SciencesAbstract
Abstract Background & Objective: The objective of the present study was to evaluate the effect of different statins (HMG-CoA reductase inhibitors) on gastric and duodenal ulcer in rats. Methods: The effect of different statins on gastric and duodenal ulcers were evaluated by using different experimental models such as acetic acid induced chronic gastric ulcer, pylorus ligation induced gastric ulcer, ethanol induced gastric ulcer, stress induced gastric ulcer and cysteamine induced duodenal ulcer. Results: The different statins tested in the present showed variable effects in different models of gastric ulcers and cysteamine induced duodenal ulcer. Atorvastain showed anti-ulcer activity in three models; pylorus ligation, ethanol induced gastric ulcer and acetic acid induced chronic gastric ulcers. Simvastatin showed a decrease in free acidity in pylorus ligated rats while lovastatin did not influence gastric and duodenal ulcer formation or healing of gastric ulcers. Interpretation & Conclusion: The atorvastatin showed significant effect on the healing and development of gastric ulcers while other statins did not influence ulcer healing or ulcer formation. It was concluded atorvastatin possess anti-ulcer effect in rats and all the tested statins may be safe for administration to patients suffering from peptic ulcer disease.
References
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. GottoAMReview. 2005;5:96–5.
Mazzone T. Reducing cardiovascular disease in patients with diabetes mellitus. Curr Opin Cardiol; 2005.
El-Hajj II, Mourad FH, Shabb NS, Barada K. Atorvastatininduced severe gastric ulceration: a case report. World J Gastroenterol. 2005 5;28:11–20.
Stamm JA, Ornstein DL. The role of statins in cancer prevention and treatment. Oncology. Williston: Park; 2005.
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. South Med J. 2005;98(5):534–40.
Asad M, Shewade DG, Koumaravelou K, Abraham BK, Vasu S, Ramaswamy S. Gastric anti-secretary and antulcer activity of oxytocin in rats and guinea pigs. Life Sci; 2001.
Vincent GP, Galvin GB, Rutkowski JL, et.al. Body orientation, food deprivation and potentiation of restraint induced gastric lesions. Gastroenterol Clin Biol; 1977.
Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Nakayama H, Ohnishi Y. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug. World J Gastroenterol. 2005 2;21(11):1040–3.
PluharWA case of possible lovastatin-induced pancreatitis in concomitant Gilbert syndrome. Wien Klin Wochenschr; 1989.
Martinsen TC, Skogaker NE, Bendheim MO,Waldum HL. Antral G cells;. in.
JM C, et al. The Robbin’s Pathologic basis of disease. 2003;p. 787–802.
Olsson AG. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am J Cardiol;2001(87):33–6.
Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med;2001:111–185.
JR WSD. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;p. 279–1615.
Bonetti PO, Lerman LO. Napoli C, Lerman A Statin effects beyond lipid lowering—are they clinically relevant? Euro Heart J;2003:24–225.
SH LLW. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation;2002:105–415.
Shay H, Komarov SA. Fele SS, Meranze D, Gruenstein H, Siplet H. A simple method for uniform production of gastric ulceration in rat. Gastroenterology; 1945.
Kulkarni SK. Hand book of experimental pharmacology. New Delhi: Vallabh prakashan; 1999.
Ganguly AK. A method for quantitative assement of experimentally produced ulcers in stomach of rats. Experientia; 25:1124.
Parmar NS, Desai JK. A review of the current methodology for the evaluation of gastric and duodenal anti ulcer agents. Indian J Pharmacol. 1993;25:120–135.
Wang JZ, Wuy J, Rao CM, Gao MT. Li WG. Effect of recombinant human basic fibroblast growth factor on stomach ulcers in rats and mice. Acta Pharmacol Sin;1999:209– 8.
Szabo S. Animal model for human disease: Duodenal ulcer disease. Amer J Pathol. 1978;73:273–276.
Desai JK, Goyal RK, Parmar NS. Characterization of dopamine receptor subtypes involved in experimentally induced gastric and duodenal ulcers in rats. J Pharm Pharmacol. 1999;51:187–92.
Soll AH. Pathogenesis of peptic ulcers and implication for therapy. New Eng J Med. 1990;322:909–16.
Surendra S. Evaluation of gastric anti-ulcer activity of fixed oil of tulsi and possible mechanism. Indian J Exp Biol;1999:36–3.
Debnath PK, Gode KO, Govinda DD, Sanyal AK. Effect of propranolol on gastric secretion in rats. vol. 51. Br J Pharmacol; 1974.
Corne SJ, Morrissey SM, Woods RJ. A method for the quantitative estimation of gastric barrier mucus;.
